Amendments to the Specification

In the Brief Description of the Drawings, please make the following changes:

Replace the paragraph beginning at page 22, line 11, with the following paragraph:

FIGURE 1A-C. Forms of Immune Augmentation. This figure demonstrates an overview of various embodiments of the invention, including "immunoadjuvant" embodiments wherein the immunopotentiating pootein is simply admixed with a compound against which an immune response is desired (top panel), or where ~~and~~ an actual heteroconjugate is formed between the immunopotentiating protein and the compound (middle panel). In the bottom panel is shown an embodiment wherein the immunopotentiating ligand is actually a bifunctional ~~cojugate~~ conjugate formed between two antibodies.

Replace the paragraph beginning at page 22, line 22, with the following paragraph:

FIGURE 2A-1-B-4. Activation of peripheral lymph node T cells from anti-CD3-treated C3H mice as assessed by flow cytometry (FCM). Two color FCM from control animals and those treated with, 4, 40, or 400 μg of anti-CD3 are displayed as contour plots on a logarithmic scale. Intensity of green FITC fluorescence is plotted along the x-axis and red (B-phycoerythrin) fluorescence is plotted along the 7-axis. (A) Anti-CD4 staining on the x-axis and anti-IL-2 receptor (I1-2R) staining on the y-axis. (B) Anti-CD3 staining on the x-axis and anti-Thy-1 staining on the y-axis. C3H/HeN MTV mice were killed 18 hours after intravenous injection of purified anti-CD3 (MAb 145-2C11) that was grown and purified as described (24). Femoral, axillary, and mesenteric lymph nodes were removed and dissociated into a single-cell suspension and FCM analysis was performed (25). Cells were stained with FITC-anti-CD3 or FITC-anti-CD4 (MAb GK1.5) (Becton Dickinson), and biotin-conjugated anti-IL-2R (MAb 3C7) or biotin-

conjugated MAb to Thy-1.2 (Becton Dickinson), then counterstained with B-phycoerythrin-conjugated egg white avidin (Jackson Immuno Research Laboratories). These results show that low dose (4 ug) anti-CD3 treatment activates T cells as evidenced by IL-2R expression but does not modulate T cell receptors.

Replace the paragraph beginning at page 23, line 33, with the following paragraph:

FIGURE 4A-B. Colony Stimulating Factor (CSF) in serum of mice after injection of anti-CD3. Pooled sera from three animals were placed at 6% final dilution with murine bone marrow cells, and the number of colonies were counted after 7 days. Each sample was tested in duplicate and the results were averaged. In all cases, duplicate values differed by no more than 5%. A: Mice received 400μg anti-CD3 Ig(▪) , or 250μg of $F(ab')_2$ fragments of anti-CD3 (o). (The number of colonies at 3h for anti-CD3 treated mice was more than 300.) B: Number of colonies after various doses of anti-CD3. Serum was collected 3 h after injection. These results show that anti-CD3 in vivo induces lymphokines including colony stimulating factors.

Replace the paragraph beginning at page 24, line 12, with the following paragraph:

FIGURE 5A-B. Clinical Response to anti-CD3 (OKT3) Treatment. A: Increased allogenic MHC response in patients treated with OKT3. B: Proliferation of T cells before and after OKT3 treatment in the presence (cross-hatched bars) or absence (closed bars) of rIL-2 suggest that in vivo treatment with OKT3 activates human T cells.

Replace the paragraph beginning at page 24, line 34, with the following paragraph:

FIGURE ~~87~~ 8A-B. IL-2R expression on T cells from SEB-treated mice. Mice were treated with increasing doses of SEB (0, 5, 50, 250μg). I1-2R expression after 18 hours was compared using flow cytometry and showed enhanced expression. Dose response was observed.

Replace the paragraph beginning at page 25, line 12, with the following paragraph:

FIGURE 10A-1-B-3. Expansion of $V_\beta 8^+$ cells in SEB-treated mice. Three days after treatment of mice with SEB, spleen cells were incubated with anti-$V_\beta 8$ and $V_\beta 8^+$ cells were assayed by flow cytometry. Expansion of $V_\beta 8^+$ cells was observed due to SEB treatment.

Replace the paragraph beginning at page 27, line 13, with the following paragraph:

FIGURE 16A-B. In vivo immune stimulation of mice administered a heteroconjugate. Panel A: IgG anti-FITC antibody production in anti-CD3 treated mice immunized with FITC-BSA in complete Freunds adjuvant (CFA) or PBS, compared to ELISA measurements of sera from control mice (open bars). Panel B: IgG anti-FITC antibody production measured from sera of FITC-anti-CD3 treated mice (left-hatched bars) compared to FITC-normal Hamster Ig (cross-hatched bars) measured by ELISA performed on day 10 bleeds.

Please replace the Abstract with the amended Abstract attached hereto.